Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | RXRA | P19793 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595117 | 0.88 | PRKAA2 (0.60) | PRKAA2SMN1; SMN2RXRANR1I2NR4A2 | |
| SCHEMBL27685938 | 0.88 | PRKAA2 (0.60) | PRKAA2SMN1; SMN2RXRANR1I2NR4A2 | |
| SCHEMBL1744135 | 0.87 | PRKAA2 (0.67) | PRKAA2SMN1; SMN2RXRANR1I2NR4A2 | |
| SCHEMBL18791302 | 0.86 | PRKAA2 (0.61) | PRKAA2SMN1; SMN2RXRANR1I2NR4A2 | |
| Toluene SCHEMBL27930704 | 0.85 | PRKAA2 (0.57) | PRKAA2SMN1; SMN2RXRANR1I2NR4A2 | |
| SCHEMBL13861857 | 0.85 | PRKAA2 (0.65) | PRKAA2SMN1; SMN2RXRANR1I2NR4A2 | |
| SCHEMBL5154877 | 0.84 | PRKAA2 (0.56) | PRKAA2SMN1; SMN2RXRANR1I2NR4A2 | |
| SCHEMBL10074065 | 0.82 | PRKAA2 (0.68) | PRKAA2SMN1; SMN2RXRANR1I2NR4A2 | |
| SCHEMBL29275375 | 0.82 | PRKAA2 (0.61) | PRKAA2SMN1; SMN2RXRANR1I2NR4A2 | |
| SCHEMBL6068355 | 0.82 | PRKAA2 (0.61) | PRKAA2SMN1; SMN2RXRANR1I2NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387561-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-Ý2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL¨-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN Laboratories Limited (IN) | 2011-11-23 | — | — | EP | claimed |
| WO-2010089770-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-[2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL]-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LABORATORIES LIMITED (IN) | 2010-08-12 | — | — | WO | claimed |
| CN-109422681-A | A kind of preparation method of Pitavastatin Calcium intermediate | 浙江京新药业股份有限公司 | 2019-03-05 | — | — | CN | disclosed |
| CN-103508948-A | Method for preparing pitavastatin calcium | ASYMCHEM LAB TIANJIN CO LTD | 2014-01-15 | — | — | CN | disclosed |
| US-8487105-B2 | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-07-16 | — | — | US | disclosed |
| US-8487105-B2 | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-07-16 | — | — | US | disclosed |
| US-8487105-B2 | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-07-16 | — | — | US | disclosed |
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2012-01-19 | — | — | US | disclosed |
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2012-01-19 | — | — | US | disclosed |
| EP-2387561-A2 | IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE (3R,5S)-7-Ý2-CYCLOPROPYL-4-(4-FLUOROPHENYL) QUINOLIN-3-YL¨-3,5-DIHYDROXY-6(E)-HEPTENOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN Laboratories Limited (IN) | 2011-11-23 | — | — | EP | disclosed |
| EP-1375487-B1 | PROCESS FOR PRODUCING QUINOLINE-3-CARBOXYLIC ACID COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-6852862-B2 | Process for producing quinoline-3-carboxylic acid compound | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| CN-1494531-A | Process for producing quinoline-3-carboxylic acid compound | ס����ϸ��ѧ����˾ | 2004-05-05 | — | — | CN | disclosed |
| US-20040073034-A1 | Process for producing quinoline-3-carboxylic acid compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1375487-A1 | PROCESS FOR PRODUCING QUINOLINE-3-CARBOXYLIC ACID COMPOUND | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030125355-A1 | Processes for preparing quinoline derivatives and intermedias thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-07-03 | — | — | US | disclosed |
| EP-1262476-A1 | PROCESSES FOR PREPARING QUINOLINE DERIVATIVES AND INTERMEDIATES THEREOF | KURARAY CO., LTD. (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-0535548-B1 | Inhibitor of atherosclerotic intimal thickening | NISSAN CHEMICAL IND LTD (JP) | 2001-11-21 | — | — | EP | disclosed |
| US-6162798-A | Inhibitor of atherosclerotic intimal thickening | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2000-12-19 | — | — | US | disclosed |
| EP-0535548-A1 | Inhibitor of atherosclerotic intimal thickening | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1993-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | PCSK9, HMGCR, HDLBP | PRKAA2 679/4885SMN1; SMN2 3978/4885RXRA 695/4885 |
| US-20030125355-A1 | Processes for preparing quinoline derivatives and intermedias thereof | NQO1, ADH1B, IDH3B | PRKAA2 2107/4885SMN1; SMN2 2157/4885RXRA 851/4885 |
| US-20040073034-A1 | Process for producing quinoline-3-carboxylic acid compound | ADH1C, ADH5, CBR3 | PRKAA2 311/4885SMN1; SMN2 4611/4885RXRA 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.